Moreover, BRCA1- or TP53-deficiency could serve aspredictive biomarker of the sensitivity of a tumor to POLθ inhibitorsin combination with PARPi and DNA-PK inhibitors, respectively. This evidence concerns the gene PRKDC and neoplasm.